2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access ~ Representation ~ Population Health, Technology and Procedures, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Immunotherapy, Artificial Intelligence (AI), Machine Learning, Biological Processes, Pathogenesis, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Clinical Practice (Health Services and Quality), Practice Models, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Measurable Residual Disease, ALL, Research, Fundamental Science, Translational Research, Clinical Research, Epidemiology, Real-World Evidence, Study Population, Human, Adult, Elderly, Pediatric, Young Adult, Animal Model
PAPER

1575 Dissecting the clonal distribution of IKZF1 copy number deletions in adult ph- B-cell acute lymphoblastic leukemia

Luca Vincenzo Cappelli, MD, PhD, Alessandro Natoni2, Deborah Cardinali3, Francesca Kaiser4, Mariangela Di Trani5, Sabina Chiaretti, MD6, Robin Foà, MD7
1 Sapienza University of Rome, Rome, Italy
2 Sapienza University of Rome, Rome, Italy
3 Sapienza University of Rome, Rome, Italy
4 Sapienza University of Rome, Rome, Italy
5 Sapienza University of Rome, Rome, Italy
6 Sapienza University of Rome, Rome, Italy
7 Sapienza University of Rome, Rome, Italy

Introduction. IKZF1 deletions (IKZF1loss) and the IKZF1plus genotype are frequently present at diagnosis in adult acute lymphoblastic leukemia (ALL). While these events (namely IKZF1plus) are well established adverse prognostic factors in Ph+ ALL, their role remains inconclusive in Ph- and Ph-like ALL. IKZF1loss is thought to arise early in leukemogenesis, with co-lesions defining IKZF1plus residing in the same cell - an inference drawn from bulk sequencing - with no direct single-cell evidence to date. We applied single-cell DNA/protein sequencing to diagnostic ALL samples to position IKZF1loss within the clonal hierarchy and define its interactions with co-occurring genomic aberrations.

Methods. We evaluated 7 diagnostic bone marrow samples (>75% blasts; 4 Ph-like, 3 non-Ph-like; median age 46 years, range 31-56) with Multiplex Ligation-dependent Probe Amplification (MLPA)-defined IKZF1loss (5 loss-of-function, 1 dominant-negative, 1 atypical; 5/7 meeting IKZF1plus criteria), in addition to 1 IKZF1-wildtype sample as negative control. After dead-cell depletion (viability >90%), cells were loaded on a Tapestri instrument (Mission Bio™ San Francisco, CA) with a custom 346-amplicon DNA and 32-antibody protein panels and sequenced on a NovaSeq X Plus (80×/amplicon, 750×/AOC per cell); 37,092 cells in total were analyzed. Ploidy was referenced to immunophenotypically normal clusters/mutation-wildtype compartment within patients’ samples. Analyses used Mosaic v3.17.0.

Results. Twenty-one driver single nucleotide variants (SNVs, median 3/patient, range 1–5) defined a median of 5 clones (range 2–8). Concordance with targeted DNA sequencing was 82% (9/11 bulk-reported variants recovered, 2/11 genes outside the custom panel). Single-cell resolution identified 12 additional low-frequency variants below bulk detection. Regarding copy number variations (CNVs), concordance with MLPA was 100%, down to exon resolution. IKZF1loss was truncal (present in every blast subpopulation) in 6/7 patients (all 5 IKZF1plus and 1 IKZF1loss -only case). In the other IKZF1loss -only patient the event was subclonal, as it was restricted to one NRAS-mutant population; this was the only patient who never relapsed at a follow-up of 107 months. Regarding IKZF1plus patients, 4/5 were defined by a PAX5deletion. In all cases, every IKZF1-deleted blast also carried the PAX5 loss and no subpopulation harbored exclusively one lesion, establishing IKZF1plus as a composite genotype of the founding clone. In 1 case, IKZF1loss and PAX5 exon 1 loss were truncal and gave rise to 2 mutually exclusive subclones: one developing a PAX5 full loss and a NRAS G13D mutation, the other a TP53 deletion (but no NRAS -mutation). Overall, in all 7 patients other pathogenic CNV aberrations were also equally truncal (e.g. BTG1, ETV6, CD200, MTAP). With regard to SNVs, mutations affecting signaling genes (JAK1/2, KRAS, NRAS, PTPN11) occurred in all 7 cases but were all subclonal, indicating that they arose later in the clonal hierarchy. Furthermore, the 2 IKZF1loss -only patients harbored additional clonal mutations (shared by all blasts, i.e. SETD2, biallelic PAX5), while in the 5 IKZF1plus cases the founding genotype was entirely CNV-driven, with few blast clusters carrying the complete CNV aberrations but no mutations. The mutational architecture was linear in 2 cases and branched in 5, always on the signaling axis and converging at each branch point on one pathway; one patient branched on the CNV axis alone. Concurrent deletions and mutations of the same locus in the same cell explained hemizygous mutations in 2 patients. Finally, protein analysis showed that in 3/7 patients a single SNV subclone clustered preferentially within one immunophenotypic cluster (observed/expected 2.1–6.2, FDR<0.05). The discriminating antigens were few and recurrent: CD45, CD44, CD10, each in 2/7 patients.

Conclusions. These findings demonstrate that IKZF1loss is a founding event in ALL pathogenesis and that other CNVs, especially those defining the IKZF1plus genotype, are established at the same level prior to any further genomic aberrations. IKZF1loss alone relies on other pathogenic mutations/aberrations, while the genomic complexity of IKZF1pluscan initiate a self-sustained leukemogenesis process. Later cooperating lesions belonging to different pathways such as RAS and JAK/STAT contribute to clonal evolution and generate multiple co-existing, and often phenotypically distinct, subclones.

Luca Vincenzo Cappelli, MD, PhD: No relevant conflicts of interest to declare.